REATA PHARMACEUTICALS INC License Agreements
22 Contracts & Agreements
- Seventh Supplement to Exclusive License and Supply Agreement, dated as of February 28, 2022 between Reata Pharmaceuticals, Inc. and Kyowa Hakko Kirin Co., Ltd (Filed With SEC on August 8, 2022)
- Seventh Supplement to Exclusive License and Supply Agreement, dated as of February 28, 2022 between Reata Pharmaceuticals, Inc. and Kyowa Hakko Kirin Co., Ltd (Filed With SEC on May 10, 2022)
- Amendment No. 1 to Exclusive License Agreement, dated as of April 5, 2022, by and between the KU Center for Technology Commercialization, Inc. and the Registrant, dated as of, as... (Filed With SEC on May 10, 2022)
- Exclusive License and Supply Agreement between the Registrant and Kyowa Hakko Kirin Co. Ltd., dated as of December 24, 2009 (Filed With SEC on February 28, 2022)
- Exclusive License Agreement between the KU Center for Technology Commercialization, Inc. and the Registrant, dated as of September 26, 2014 (Filed With SEC on February 28, 2022)
- Exclusive License Agreement between the Trustees of Dartmouth College and the Registrant, dated as of December 16, 2009, as amended (Filed With SEC on February 28, 2022)
- Exclusive Patent License Agreement among the Board of Regents of The University of Texas System, The University of Texas M.D. Anderson Cancer Center, and the Trustees of Dartmouth... (Filed With SEC on February 28, 2022)
- Amendment No. 2 to the Exclusive License Agreement between the Trustees of Dartmouth College and the Registrant, dated as of August 17, 2021 as amended (Filed With SEC on November 8, 2021)
- Amendment No. 2 to the Exclusive Patent License Agreement among the Board of Regents of The University of Texas System, The University of Texas M.D. Anderson Cancer Center, and... (Filed With SEC on November 8, 2021)
- Amended and Restated License Agreement, dated as of October 9, 2019 (Filed With SEC on October 10, 2019)
- Sixth Supplement to Exclusive License and Supply Agreement, dated August 22, 2019, between Reata Pharmaceuticals, Inc. and Kyowa Kirin Co., Ltd (Filed With SEC on August 22, 2019)
- Fifth Supplement to Exclusive License and Supply Agreement, dated August 22, 2019, between Reata Pharmaceuticals, Inc. and Kyowa Kirin Co., Ltd (Filed With SEC on August 22, 2019)
- Fourth Supplement to Exclusive License and Supply Agreement, dated as of December 6, 2017, between Reata Pharmaceuticals, Inc. and Kyowa Hakko Kirin Co., Ltd (Filed With SEC on December 7, 2017)
- Third Supplement to Exclusive License and Supply Agreement, dated as of December 6, 2017, between Reata Pharmaceuticals, Inc. and Kyowa Hakko Kirin Co., Ltd (Filed With SEC on December 7, 2017)
- SUPPLEMENT TO EXCLUSIVE LICENSE AND SUPPLY AGREEMENT Regarding Phase 3 Clinical Study (CTD-PAH) in Japan (Filed With SEC on March 22, 2016)
- LICENSE AGREEMENT between REATAPHARMACEUTICALS, INC. and ABBOTT PHARMACEUTICALS PR LTD. Dated as of September 21, 2010 TABLE OF CONTENTS (Filed With SEC on February 8, 2016)
- LICENSE AGREEMENT between REATAPHARMACEUTICALS, INC. and ABBOTT PHARMACEUTICALS PR LTD. Dated as of September 21, 2010 TABLE OF CONTENTS (Filed With SEC on January 4, 2016)
- EXCLUSIVE LICENSE and SUPPLY AGREEMENT by and between REATAPHARMACEUTICALS, INC. and KYOWA HAKKO KIRIN CO. LTD. (Filed With SEC on January 4, 2016)
- EXCLUSIVE LICENSE AGREEMENT between ReataPharmaceuticals, Inc. and KU Center for Technology Commercialization, Inc. (Filed With SEC on January 4, 2016)
- EXCLUSIVE LICENSE AGREEMENT between ReataPharmaceuticals, Inc. and KU Center for Technology Commercialization, Inc. (Filed With SEC on January 4, 2016)
- REATA PHARMACEUTICALS, INC. - DARTMOUTH EXCLUSIVE LICENSE AGREEMENT (Filed With SEC on January 4, 2016)
- EXCLUSIVE PATENT LICENSE AGREEMENT AMONG THE UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER DARTMOUTH COLLEGE AND REATA DISCOVERY, INC. TABLE OF CONTENTS (Filed With SEC on January 4, 2016)
